NAMS
NewAmsterdam Pharma Co N.V.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 20 to Mar 11 ▼ 9 days of insider sells: $38.2M by 3 insiders, avg $32.71
- May 26 ▼ 1 insider sell $2.3M at $35.69
- Jun 22 ▼ 1 insider sell $1.2M at $30.20
- Jul 20 ▼ 1 insider sell $3.2M at $30.34
- Jul 24 ▲ NewAmsterdam Pharma announced that the EMA's CHMP has adopted a posi…
- Aug 3 Trial readout: T-90d Trial Readout: Obicetrapib (Phase 3)
- Aug 5 ▲ NewAmsterdam Pharma reported Q2 2026 results alongside the announcem…
- Aug 14 ▼ Short interest jumps 27.1% to 12.65M
- Sep 4 ▼ 1 insider sell $40.5K at $25.32
- Sep 14 ▲ 1 insider buy $226.5K at $22.65
- Sep 30 ▼ 1 insider sell $1.3M at $25.03
- Oct 15 ▲ Short interest falls 25.9% to 14.11M
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $226.5K at an average $22.65. 5 insiders sold $46.2M. Price is 14% below their cost.
- InstitutionsMIXED
Q3 2026: 21 added (1 new), 17 trimmed or exited.
- AnalystsBULLISH
21 of 23 rate it Buy or better.
- Short sellersSTEADY
Short interest −14.9% to 12.01M shares. 8.3 days to cover, ≈10.0% of shares.
- TrendDOWNTREND
9% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| AMERICAN CENTURY COMPANIES INC | ADD | $21.0M |
| MORGAN STANLEY | ADD | $20.3M |
| Qube Research & Technologies Ltd | DOUBLED | $9.1M |
| Jump Financial, LLC | DOUBLED | $8.7M |
| JANE STREET GROUP, LLC | TRIM | $8.4M |
| VICTORY CAPITAL MANAGEMENT INC | ADD | $7.5M |
| BARCLAYS PLC | DOUBLED | $6.8M |
| HRT FINANCIAL LP | TRIM | $5.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
23 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Cantor Fitzgerald MAINTAIN | Overweight |
| Nov 5, 2026 | Needham MAINTAIN | Buy |
| Oct 5, 2026 | RBC Capital MAINTAIN | Outperform |
| Sep 8, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 6, 2026 | RBC Capital MAINTAIN | Outperform |
| Jun 30, 2026 | RBC Capital MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kastelein Johannes Jacob Pieter Chief Scientific Officer Sep 30, 2026 | EXERCISE | 50,246 sh |
Kastelein Johannes Jacob Pieter Chief Scientific Officer Sep 30, 2026 | SELL | $1.3M |
Davidson Michael H. Chief Executive Officer Sep 14, 2026 | BUY | $226.5K |
Smither John W Director Sep 4, 2026 | SELL | $40.5K |
Gunning Robert William Vice President, Controller Sep 1, 2026 | AWARD | 14,000 sh |
Gunning Robert William Vice President, Controller Sep 1, 2026 | AWARD | 3,200 sh |
Kooij Louise Frederika Chief Accounting Officer Jul 20, 2026 | EXERCISE | $893.6K |
Kooij Louise Frederika Chief Accounting Officer Jul 20, 2026 | EXERCISE | $297.5K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
8 filings · 4 bullish · 0 bearish · 4 neutral- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 11,941,763…
Fidelity's marginal increase is routine portfolio rebalancing by a passive holder. Monitor future 13G filings for any material changes in stake size or a conversion to 13D, which would signal…
- NEUTRAL PRESS-RELEASENov 4, 2026
NewAmsterdam Pharma reported Q3 2026 net loss of $17.4M, significantly narrower than the $72.0M…
The EC approval is a major regulatory milestone but the stock's reaction will depend on the PREVAIL interim analysis result expected in Q1 2027, which is the key catalyst for obicetrapib's…
- NEUTRAL 8-KSep 29, 2026
NewAmsterdam Pharma announced the dosing of the first patient in SPINOZA, a Phase 2b trial…
SPINOZA is a proof-of-concept expansion into Alzheimer's disease, but the primary endpoint readout is at Week 52, no near-term binary catalyst. The BROADWAY biomarker signal provides scientific…
- BULLISH SC 13D/ASep 22, 2026
Frazier Life Sciences funds filed Amendment No. 7 to their Schedule 13D on NewAmsterdam Pharma…
Frazier's consistent open-market buying over nine consecutive trading days signals strong conviction and a potential floor near $21. The absence of any stated change in purpose suggests this is a…
All NAMS filing & press-release reports (8)
- SC 13G/A reportNov 5, 2026
- PRESS-RELEASE reportNov 4, 2026
- 8-K reportSep 29, 2026
- SC 13D/A reportSep 22, 2026
- INSIDER-BUY reportSep 15, 2026
- 8-K reportAug 5, 2026
- 8-K reportJul 24, 2026
- PRESS-RELEASE reportApr 8, 2026